

ESMO 2014 Industry Satellite Symposium

BEYOND SYMPTOM CONTROL: Continued Advances in Targeting Gastroenteropancreatic Neuroendocrine Tumors

Friday, 26 September 2014
18.00–20.00
San Sebastian Auditorium

FACULTY

Jaume Capdevila, MD (Chair)
Vall d'Hebron University Hospital
Barcelona, Spain

Ulrich-Frank Pape, MD
Charité University Hospital
Berlin, Germany

Matthias Weber, MD
Johannes Gutenberg University Mainz
Mainz, Germany

CONTINUING EDUCATION

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

This activity has been approved for *AMA PRA Category 1 Credit™*.

This activity is provided
by prIME Oncology.



This educational activity
is supported by IPSEN.

AGENDA

- Welcome and introduction
Jaume Capdevila, MD
- 18.00 How much do you know about gastroenteropancreatic neuroendocrine tumors (GEP-NETs)? Test your knowledge
Jaume Capdevila, MD
- 18.15 GEP-NETs: A closer look at the characteristics of these diverse tumors
Ulrich-Frank Pape, MD
- 18.35 New directions in the treatment of GEP-NETs: Shifting from symptom management to targeting tumors
Matthias Weber, MD
- 19.00 Clinical scenario #1—Advanced, grade 2 neuroendocrine tumor in the midgut: Watch and wait or initiate treatment?
Jaume Capdevila, MD
- 19.20 Clinical scenario #2—Exploring treatment options for patients with symptomatic, progressive GEP-NETs
Ulrich-Frank Pape, MD
- 19.40 Challenge the experts: Panel discussion
All faculty
- 19.50 Looking forward: prIME Points™ and expert recommendations
Jaume Capdevila, MD
- 20.00 Adjourn